NCT05338177 (BOOST_TX_SubA) is a Phase 1 clinical trial of Immunosuppression reduction in COVID-19, sponsored by Medical University of Vienna.

Who is sponsoring NCT05338177?

NCT05338177 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT05338177?

Interventions in NCT05338177: Immunosuppression reduction, No immunosuppression reduction.

Is NCT05338177 still recruiting?

NCT05338177 is currently status unknown. Last updated 21 April 2022.

Last reviewed 2022-04-21 · How we verify

NCT05338177: BOOST_TX_SubA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients

Status unknown Phase 1 Last updated 21 April 2022

What this trial tests

Phase 1 trial testing Immunosuppression reduction in COVID-19 in 40 participants. Status unknown.

Timeline

15 November 2021

Primary endpoint
15 January 2022

14 November 2022

Quick facts

Lead sponsor	Medical University of Vienna
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	40
Start date	15 November 2021
Primary completion	15 January 2022
Estimated completion	14 November 2022
Sites	1 location across Austria

Drugs / interventions tested

Immunosuppression reduction — full drug profile →
No immunosuppression reduction

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Medical University of Vienna

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mycophenolate has been identified as risk factor for non-response to SARS-CoV-2 vaccination in kidney transplant recipients. Safety and efficacy of temporarily stopping of mycophenolate (or azathioprine) to increase vaccine response has not been established. This is a non-randomized, controlled pilot study including up to 40 kidney transplant recipients not responding to at least three previous SARS-CoV-2 vaccine doses. Mycophenolate or azathioprine will be stopped for two weeks peri-vaccination starting one week before vaccination until one week after vaccination. Allocation to mycophenoalte or azathioprine discontinuation arm will be based on an overall risk assessment by the transplant physician and patient preference. Patients not stopping mycophenolate or azathioprine will serve as control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Immunosuppression reduction

Trials testing the same drug.

NCT07206277 — Fibroscan to Guide Post Transplant Immunosuppression Minimization · NA · recruiting
NCT04177095 — Immune Monitoring to Facilitate Belatacept Monotherapy · Phase 4 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05338177 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 21 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05338177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing